Latest Healthcare News

Blue Star Helium has commenced drilling the Jackson 2 well at its Galactica helium project in Colorado, marking a key step in its ongoing development program. The well is progressing towards the Lyons Formation target with plans for flow testing and production tie-in.

Peak Rare Earths made significant strides in the March 2025 quarter, progressing its Ngualla Rare Earth Project, securing A$8.5 million in capital, and benefiting from a surge in rare earth prices driven by growing EV demand and evolving Chinese regulations.

Opyl Limited reports strong progress in AI-driven clinical trial optimisation with active commercial initiatives, strategic partnerships, and a planned capital raise to support growth amid tight cash reserves.

OncoSil Medical has reported a remarkable 233% increase in dose sales for Q3 FY25, alongside significant regulatory approvals and strategic expansions that position the company for accelerated growth.

Careteq Limited reports strong Q3 FY25 progress with near completion of its 1-System platform integration, revenue growth exceeding forecasts, and new strategic partnerships broadening its healthcare footprint.

4DMedical Limited reports a 103% surge in year-to-date revenue, secures major contracts with leading healthcare providers, and advances its CT:VQ™ technology towards FDA clearance.

Radiopharm Theranostics has bolstered its cash position with an $8 million placement from Lantheus Holdings, now its largest shareholder. New clinical data highlight promising advances in brain metastases detection and HER2-targeted radiopharmaceutical therapies.

ReNerve Limited reported a 39% sales increase in Q3 FY25 alongside compelling clinical validation of its NervAlign® Nerve Cuff and strategic international partnerships, positioning the company for broader market penetration.

Pacific Edge’s Cxbladder Plus and Triage 1 diagnostic tests are set for significant Medicare reimbursement increases, potentially reshaping the company’s US market prospects.

Centuria Capital No. 2 Fund’s latest quarterly report confirms full compliance with note terms and stable financial arrangements, reassuring investors of its secure position.

Uscom Limited reported a 14% rise in Q3 customer receipts to $0.73 million, even as cash reserves dropped 38% to $1.34 million, reflecting increased operating costs and global market pressures.

Echo IQ Limited marked a pivotal quarter with FDA clearance for EchoSolv AS, strategic US partnerships, and a clear path toward reimbursement and broader commercialisation.